390 related articles for article (PubMed ID: 34455083)
1. The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay.
Salvagno GL; Henry BM; Lippi G
Int J Infect Dis; 2021 Oct; 111():65-67. PubMed ID: 34455083
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine.
Carta M; Marinello I; Cappelletti A; Rodolfi A; Cerrito E; Bernasconi C; Gottardo M; Dal Lago F; Rizzetto D; Barzon E; Giavarina D
Am J Clin Pathol; 2022 Feb; 157(2):212-218. PubMed ID: 34463321
[TBL] [Abstract][Full Text] [Related]
3. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.
Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y
Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response.
Di Meo A; Miller JJ; Fabros A; Brinc D; Hall V; Pinzon N; Ierullo M; Ku T; Ferreira VH; Kumar D; Pasic MD; Kulasingam V
J Appl Lab Med; 2022 Jan; 7(1):57-65. PubMed ID: 34342347
[TBL] [Abstract][Full Text] [Related]
7. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
Salvagno GL; Henry BM; di Piazza G; Pighi L; De Nitto S; Bragantini D; Gianfilippi GL; Lippi G
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34064509
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
11. Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study.
Nah EH; Cho S; Park H; Kim S; Noh D; Kwon E; Cho HI
J Med Virol; 2022 Oct; 94(10):4719-4726. PubMed ID: 35655438
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
13. Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Lippi G
EJIFCC; 2022 Aug; 33(2):166-174. PubMed ID: 36313914
[TBL] [Abstract][Full Text] [Related]
14. Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA.
Danese E; Montagnana M; Salvagno GL; Gelati M; Peserico D; Pighi L; de Nitto S; Henry BM; Porru S; Lippi G
J Med Biochem; 2021 Sep; 40(4):335-340. PubMed ID: 34616223
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization.
Salvagno GL; Lippi G
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746499
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine.
Lo Sasso B; Agnello L; Giglio RV; Gambino CM; Ciaccio AM; Vidali M; Ciaccio M
Sci Rep; 2022 May; 12(1):8679. PubMed ID: 35606426
[TBL] [Abstract][Full Text] [Related]
17. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
Salvagno GL; Pighi L; Henry BM; Valentini M; Tonin B; Bragantini D; Gianfilippi G; De Nitto S; Plebani M; Lippi G
Clin Chem Lab Med; 2023 Jun; 61(7):1343-1348. PubMed ID: 36722026
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
Clin Chem Lab Med; 2021 Sep; 59(10):e377-e379. PubMed ID: 34162025
[No Abstract] [Full Text] [Related]
19. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the automated LIAISON
Bonelli F; Blocki FA; Bunnell T; Chu E; De La O A; Grenache DG; Marzucchi G; Montomoli E; Okoye L; Pallavicini L; Streva VA; Torelli A; Wagner A; Zanin D; Zierold C; Wassenberg JJ
Clin Chem Lab Med; 2021 Jul; 59(8):1463-1467. PubMed ID: 33711225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
